Strategy | Costs* (€) | Mean time to HCV diagnosis† (months) | No of CHC cases | No of CHC cases avoided by acute HCV treatment |
French strategy based on anti-HCV antibody and ALT monitoring (strategy 1) | 1 324 220 | 2.2 | 2.0 | 24.9 |
European strategy based on ALT monitoring (strategy 2) | 1 132 230 | 2.0 | 2.1 | 24.9 |
Baseline-US strategy based on anti-HCV antibody and ALT monitoring (strategy 3) | 924 180 | 6.0 | 7.9 | 17.7 |
Alternative-US strategy based on HCV RNA testing (strategy 4) | 1 303 050 | 1.0 | 1.9 | 25.1 |
*Estimated costs from exposure to death.
†Mean time from exposure to HCV diagnosis.
ALT, alanine transaminase; CHC, chronic hepatitis C; HCV, hepatitis C virus; HCW, healthcare worker.